weekly_roundup
BioTechSign Daily Catalyst Roundup - November 18, 2026
Top BioTechSign catalyst names today: UCBNV, EIKN, ZBIO, CMPX, MLTX, BAYRY. FDA, clinical trial, grade-change, dilution, and sentiment signals.
BiotechSign AnalysisNovember 18, 2026
Daily Biotech Catalyst Digest: November 18, 2026
UCBNV leads the current BioTechSign screen at 100.0/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.
Top Catalyst Scores
| Ticker | Company | Score | Grade | Strongest Inputs |
|---|---|---|---|---|
| UCBNV | UCB SA | 100.0 | A | clinical activity 100% |
| EIKN | Eikon Therapeutics, Inc. | 85.5 | A | publication signal 100%, clinical activity 100%, short interest 70% |
| ZBIO | Zenas BioPharma, Inc. | 81.5 | A | clinical activity 100%, short interest 70%, publication signal 35% |
| CMPX | Compass Therapeutics, Inc. | 81.1 | A | clinical activity 92%, short interest 90%, publication signal 60% |
| MLTX | MoonLake Immunotherapeutics | 80.5 | A | clinical activity 100%, short interest 50%, publication signal 35% |
| BAYRY | Bayer AG | 79.5 | B | publication signal 100%, clinical activity 100%, dilution risk 40% |
Recent Grade-Change Queue
- NCEL (NewcelX Ltd.) currently grades F with a 14.5/100 catalyst score. Main inputs: dilution risk 62%, short interest 10%, publication signal 5%.
- JAZZ (Jazz Pharmaceuticals plc) currently grades D with a 45.6/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, PDUFA timing 35%.
- RZLT (Rezolute, Inc.) currently grades D with a 38.2/100 catalyst score. Main inputs: short interest 70%, dilution risk 62%, clinical activity 50%.
- PBYI (Puma Biotechnology Inc) currently grades C with a 56.5/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, short interest 50%.
- UCBNV (UCB SA) currently grades A with a 100.0/100 catalyst score. Main inputs: clinical activity 100%.
- SNY (Sanofi SA) currently grades B with a 73.3/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, dilution risk 12%.
- EYPT (EyePoint, Inc.) currently grades D with a 47.5/100 catalyst score. Main inputs: short interest 50%, dilution risk 47%, publication signal 40%.
- EXEL (Exelixis Inc) currently grades B with a 76.0/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, short interest 50%.
What To Watch
Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.